ArticleBMC gastroenterology2025
Resolvin D1 values in patients with alcohol-associated liver disease.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hepatoprotective effects of resolvin D1 in mice exposed to ethanol and galactosamine.Hepatology communications · 2026Article
- Validated bioanalysis of oxylipins confirms specialized pro-resolving mediator formation in vitro and in vivo.Journal of lipid research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResolvin D1 (RvD1), a specialized pro-resolving lipid mediator, has been associated with liver injury in experimental models of alcohol-associated liver disease (ALD). This study aimed to evaluate the relationship between serum RvD1 levels and clinical phenotypes of ALD.
methodsThis case-control study included 82 patients with ALD and 48 healthy controls (HCs). The ALD patients were categorized into three subgroups: alcohol-associated steatotic liver (ASL), alcohol-associated hepatitis (AH), and alcohol-associated cirrhosis (AC). Serum RvD1 levels were measured using the enzyme-linked immunosorbent assay (ELISA) test. The Fibrosis-4 (Fib-4) index was used to assess liver fibrosis in all participants. For the AH and AC groups, the Model for End-stage Liver Disease Sodium (MELD-Na) scores were calculated. Child-Pugh classification was applied to the AC patients and Maddrey's Discriminant Function was applied to the AH patients. An esophagogastroduodenoscopy was performed in the AH and AC patients to evaluate portal hypertension.
resultsThe serum RvD1 levels were significantly lower in the AH and AC groups compared to the ASL and HC groups (p < 0.001), with no significant difference between the AH and AC groups or between the ASL groups and the HC group. In the AC group, patients with ascites and/or esophageal/gastric varices had lower serum RvD1 levels compared to those without (p = 0.013 and p = 0.004, respectively). Additionally, the serum RvD1 levels decreased with advancing Child-Pugh class (p = 0.004). The serum RvD1 levels were inversely correlated with the Fib-4 scores, the MELD-Na and Child-Pugh scores in both the AC group (p < 0.05 for all).
conclusionSerum RvD1 levels are associated with the severity of ALD and may represent a promising non-invasive biomarker. However, due to the absence of an external validation cohort, these findings should be interpreted as exploratory. Further validation in independent populations is warranted to confirm the clinical utility of RvD1 in ALD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.